Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer
We are studying tucatinib plus T-DM1 to find out what the side effects are and if it works for treating HER2-positive breast cancer. We want to find out how effective tucatinib plus T-DM1 is compared to treatment with only T-DM1.
Unresectable Locally-advanced or Metastatic HER2-positive breast cancer
Male of female 18 years and older
unresectable locally-advanced or metastatic HER2-positive breast cancer
prior treatment with a taxane and trastuzumab in any setting, separately or in combination
18 - 101
Healthy Volunteers Needed
Duration of Participation
You will receive the study drugs for as long as your cancer does not get worse or you do not have bad side effects. After you are done getting treated with the study drugs, we will contact you every 9 weeks until the study closes to see how you are doing and to ask about your cancer.
Knight Cancer Institute Clinical Trials